ADC Therapeutics (ADCT) Form 3 ADC Therapeutics / Viviane Monges ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Monges Viviane

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NJ 07974

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/02/2024

3. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	68,064(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	(2)	02/01/2031	Common Shares	21,190	27.53	D
Stock Options (Right to Buy)	(3)	03/22/2031	Common Shares	9,747	28.7	D

Explanation of Responses:

1. Includes 20,000 Common Shares to be delivered in settlement of a restricted share unit award ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Shares. The RSUs were granted on June 14, 2023 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

2. This option vests over four years from February 1, 2021, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.

3. This option vests over four years from March 22, 2021, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Ameet Mallik, as Attorney-in-Fact for Viviane Monges	01/02/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.